WO2001056590A3 - Utilization of protein kinase inhibitor alpha - Google Patents

Utilization of protein kinase inhibitor alpha Download PDF

Info

Publication number
WO2001056590A3
WO2001056590A3 PCT/EP2001/001002 EP0101002W WO0156590A3 WO 2001056590 A3 WO2001056590 A3 WO 2001056590A3 EP 0101002 W EP0101002 W EP 0101002W WO 0156590 A3 WO0156590 A3 WO 0156590A3
Authority
WO
WIPO (PCT)
Prior art keywords
utilization
protein kinase
kinase inhibitor
alpha
inhibitor alpha
Prior art date
Application number
PCT/EP2001/001002
Other languages
German (de)
French (fr)
Other versions
WO2001056590A2 (en
Inventor
Ralph Knoell
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to EP01905712A priority Critical patent/EP1253931A2/en
Priority to AU2001233723A priority patent/AU2001233723A1/en
Priority to JP2001556489A priority patent/JP2003531114A/en
Publication of WO2001056590A2 publication Critical patent/WO2001056590A2/en
Publication of WO2001056590A3 publication Critical patent/WO2001056590A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention concerns the utilization of PKI alpha and/or the derivatives thereof to lower blood pressure, as beta antagonists and for the production of a medicament for the prevention and/or treatment of diseases in which a beta antagonist can be used. The invention also concerns the utilization of an inhibitor of PKI alpha or a derivative thereof to lower blood pressure, as beta agonist and for the production of a medicament for the treatment and/or prevention of diseases in which a beta agonist can be used.
PCT/EP2001/001002 2000-02-03 2001-01-31 Utilization of protein kinase inhibitor alpha WO2001056590A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01905712A EP1253931A2 (en) 2000-02-03 2001-01-31 Utilization of protein kinase inhibitor alpha
AU2001233723A AU2001233723A1 (en) 2000-02-03 2001-01-31 Utilization of protein kinase inhibitor alpha
JP2001556489A JP2003531114A (en) 2000-02-03 2001-01-31 Use of protein kinase alpha inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10004858A DE10004858A1 (en) 2000-02-03 2000-02-03 Use of protein kinase inhibitor alpha
DE10004858.7 2000-02-03

Publications (2)

Publication Number Publication Date
WO2001056590A2 WO2001056590A2 (en) 2001-08-09
WO2001056590A3 true WO2001056590A3 (en) 2002-06-20

Family

ID=7629772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/001002 WO2001056590A2 (en) 2000-02-03 2001-01-31 Utilization of protein kinase inhibitor alpha

Country Status (5)

Country Link
EP (1) EP1253931A2 (en)
JP (1) JP2003531114A (en)
AU (1) AU2001233723A1 (en)
DE (1) DE10004858A1 (en)
WO (1) WO2001056590A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (en) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
PT2056882E (en) * 2006-08-01 2012-11-19 Univ Texas Identification of a micro-rna that activates expression of beta-myosin heavy chain
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022122A1 (en) * 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
WO1998044349A1 (en) * 1997-04-03 1998-10-08 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability
US5846720A (en) * 1989-07-18 1998-12-08 Oncogene Science, Inc. Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846720A (en) * 1989-07-18 1998-12-08 Oncogene Science, Inc. Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease
WO1998022122A1 (en) * 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
WO1998044349A1 (en) * 1997-04-03 1998-10-08 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRANCIOSA J A: "BETA-ADRENERGIC BLOCKING AGENTS: PAST, PRESENT, AND FUTURE PERSPECTIVES", CORONARY ARTERY DISEASE, CURRENT SCIENCE LTD, XX, vol. 10, no. 6, September 1999 (1999-09-01), pages 369 - 376, XP001000657, ISSN: 0954-6928 *
KNOELL, R. (1) ET AL: "The protein kinase inhibitor - alpha gene: Another key to postischaemic myocardial dysfunction.", EUROPEAN HEART JOURNAL, (AUG., 1999) VOL. 20, NO. ABSTR. SUPPL., PP. 315. MEETING INFO.: XXIST CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY BARCELONA, SPAIN AUGUST 28-SEPTEMBER 1, 1999 EUROPEAN SOCIETY OF CARDIOLOGY., XP000999001 *
MARULLO S ET AL: "EXPRESSION OF HUMAN BETA-1 AND BETA-2 ADRENERGIC RECEPTORS IN ESCHERICHIA-COLI AS A NEW TOOL FOR LIGAND SCREENING", BIO-TECHNOLOGY (NEW YORK), vol. 7, no. 9, 1989, pages 923 - 927, XP001018679, ISSN: 0733-222X *
MITCHELL R D ET AL: "Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases.", BIOCHEMISTRY, (1995 JAN 17) 34 (2) 528-34., XP001021452 *
VAN PATTEN S M ET AL: "The alpha- and beta-isoforms of the inhibitor protein of the 3',5'-cyclic adenosine monophosphate-dependent protein kinase: characteristics and tissue- and developmental-specific expression.", MOLECULAR ENDOCRINOLOGY, (1992 DEC) 6 (12) 2114-22., XP001021716 *

Also Published As

Publication number Publication date
JP2003531114A (en) 2003-10-21
DE10004858A1 (en) 2001-08-16
AU2001233723A1 (en) 2001-08-14
WO2001056590A2 (en) 2001-08-09
EP1253931A2 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
PL1687305T3 (en) 1h-imidazoquinoline derivatives as protein kinase inhibitors
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
MXPA02005844A (en) Inhibitors of protein kinases.
IL175568A (en) Tyrosine kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
HUP0303363A2 (en) Use of kinase inhibitor heterocyclic compounds for preparation of pharmaceutical compositions
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2004054581A3 (en) Cyclohexyl compounds as ccr5 antagonists
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
WO2004055010A3 (en) Cyclopropyl compounds as ccr5 antagonists
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NO990522D0 (en) Use of <beta> -sheet mimetics as protease and kinase inhibitors of transcription factors
ME00549B (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
WO2003051838A3 (en) Protein kinase inhibitors
EE05241B1 (en) Use of the α-halogenoacryl derivative of distamycin
WO2001056590A3 (en) Utilization of protein kinase inhibitor alpha
WO2005082862A3 (en) Benzimidazolyl derivatives as kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001905712

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 556489

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001905712

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001905712

Country of ref document: EP